openFDA
Cure8 regulatory brief
USTEKINUMAB-AAUZ FDA label update (2026-09-30)
Medications
Ustekinumab
IL-12/23 inhibitor
Regulatory Update
Adult patients
Clinicians
Crohn's disease
Ulcerative colitis
Why This Matters
This label update confirms ustekinumab-aauz is indicated for adults with moderately to severely active Crohn's disease and ulcerative colitis and highlights safety considerations that affect treatment decisions and monitoring.
Who Should Pay Attention
Adults with Crohn's disease or ulcerative colitis considering or taking ustekinumab, their caregivers, and clinicians who prescribe or monitor biologic therapies.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
FDA DailyMed label update for ustekinumab-aauz: the full prescribing information lists indications including moderately to severely active Crohn's disease and ulcerative colitis in adults, summarizes important warnings (infections, TB evaluation, malignancy risk, hypersensitivity, PRES, avoidance of live vaccines), and details reported serious infections across approved indications.
Keep In Mind
This entry is a regulatory drug label (DailyMed) and summarizes approved indications and safety information. It is not new clinical trial data; for individual treatment decisions, consult a clinician and the complete prescribing information.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorFresenius Kabi USA, LLC
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedSep 30, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
ustekinumab FDA label update (2026-06-19)
This is an FDA drug-label record for ustekinumab that lists approved uses for Crohn’s disease and ulcerative colitis and highlights safety precautions (infections, TB screening, malignancy risk, and vaccine...
Patterns and factors associated with dose escalation during maintenance treatment for inflammatory bowel disease: a population-based cohort study.
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...
Ustekinumab-aekn FDA label update (2026-07-24)
An updated FDA drug label affects how ustekinumab is prescribed and monitored. It confirms Crohn’s disease and ulcerative colitis as approved uses and highlights safety concerns (infections, TB screening, malignancy)...